BRAF and melanoma: The crux of this resistance is the PLX4720-mediated activation of melanoma-associated fibroblasts (MAF) which confers tolerance to BRAF inhibition via a switch from BRAF-dependent ERK signaling to BRAF-independent ERK signaling in tumor cells.